Moderna doses first US patient in phase 1 trial of mRNA-4106 for solid tumours
Ella Day | May 23, 2025 | News story | Research and Development | Moderna, Oncology, START Center for Cancer Research, US
The START Center for Cancer Research has dosed the first US participant in Moderna’s phase 1 clinical trial evaluating mRNA-4106, an investigational pan-tumour antigen therapy in patients with advanced or metastatic solid tumours.
The first dose was administered at START’s San Antonio site in the US, as part of a study assessing the safety, pharmacodynamics, immunogenicity and preliminary efficacy of mRNA-4106, alone and in combination with checkpoint inhibition.
mRNA-4106 is an experimental mRNA-based therapy designed to encode multiple tumour-associated antigens, with the aim of generating broader immune responses than single-target immunotherapies. The candidate has not yet been approved for clinical use.
The trial is being conducted within START’s early-phase trial network, which includes ten global clinical sites. To date, the organisation has participated in more than 1,000 early-stage oncology studies, including trials supporting the development of 45 therapies subsequently approved by regulatory agencies.
“We’re proud to provide our patients access to this innovative treatment as part of a first-in-human trial,” commented Amita Patnaik, who led dosing at the San Antonio site and is principal investigator for the study. START’s participation in the trial reflects its ongoing focus on enabling early therapeutic access through community-based oncology research.
The trial is sponsored by Moderna, with additional study centres expected to enrol participants as part of the dose-escalation phase.
Ella Day
23/5/25
Related Content
Sharp invests $100m in US and EU manufacturing and packaging facilities
Sharp Services, a pharmaceutical packaging and sterile manufacturing specialist, has announced investments totalling $100m across …
Moderna expands use of AI-ready R&D platform
Moderna has expanded its partnership with Benchling, a cloud-based research platform, to support its broader …
Moderna authorised to upscale development of mRNA vaccines in UK
Global researcher of mRNA medicine, Moderna, has been granted authorisation by the Medicines and Healthcare …
